130 related articles for article (PubMed ID: 36216975)
21. [Prophylactic G-CSF mobilized donor lymphocytes infusion after non-myeloablative stem cell transplantation prevents relapse in patients with high-risk leukemia].
Zhao HX; Sun WJ; Li J; Qiao JX; Huang YJ; Hu HL; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):922-5. PubMed ID: 24294845
[TBL] [Abstract][Full Text] [Related]
22. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT.
Battipaglia G; Galimard JE; Labopin M; Raiola AM; Blaise D; Ruggeri A; Koc Y; Gülbas Z; Vitek A; Sica S; Diez-Martin JL; Castagna L; Bruno B; Rovira M; Moiseev I; Martino M; Grillo G; Araujo MC; Bulabois CE; Nguyen S; Socié G; Arat M; Pavlu J; Tischer J; Martin H; Corral LL; Choi G; Forcade E; McDonald A; Pane F; Bazarbachi A; Ciceri F; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Apr; 57(4):562-571. PubMed ID: 35079140
[TBL] [Abstract][Full Text] [Related]
23. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
24. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
25. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.
Rizzieri DA; Dev P; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Chao NJ
Bone Marrow Transplant; 2009 Feb; 43(4):327-33. PubMed ID: 18850014
[TBL] [Abstract][Full Text] [Related]
26. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
[TBL] [Abstract][Full Text] [Related]
27. Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO).
Patriarca F; Sperotto A; Lorentino F; Oldani E; Mammoliti S; Isola M; Picardi A; Arcese W; Saporiti G; Sorasio R; Mordini N; Cavattoni I; Musso M; Borghero C; Micò C; Fanin R; Bruno B; Ciceri F; Bonifazi F
Front Oncol; 2020; 10():572918. PubMed ID: 33178602
[TBL] [Abstract][Full Text] [Related]
28. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia.
Schmid C; Labopin M; Schaap N; Veelken H; Brecht A; Stadler M; Finke J; Baron F; Collin M; Bug G; Ljungman P; Blaise D; Tischer J; Bloor A; Kulagin A; Giebel S; Gorin NC; Esteve J; Ciceri F; Savani B; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Feb; 57(2):215-223. PubMed ID: 34750562
[TBL] [Abstract][Full Text] [Related]
29. Time-dependent analysis of adoptive immunotherapy following sequential FLAMSA-reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk myeloid neoplasia.
Weller JF; Mezger M; Seifert LL; Vogel W; Schneidawind D; Faul C; Bethge W; Lengerke C; Christopeit M
Eur J Haematol; 2022 Mar; 108(3):244-263. PubMed ID: 34902880
[TBL] [Abstract][Full Text] [Related]
30. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
[TBL] [Abstract][Full Text] [Related]
31. Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience.
El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Calmels B; Oudin C; Lemarie C; Granata A; Devillier R; Vey N; Bouabdallah R; Chabannon C; Blaise D
Exp Hematol; 2013 Jan; 41(1):17-27. PubMed ID: 23022128
[TBL] [Abstract][Full Text] [Related]
32. Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT.
Pagliuca S; Schmid C; Santoro N; Simonetta F; Battipaglia G; Guillaume T; Greco R; Onida F; Sánchez-Ortega I; Yakoub-Agha I; Kuball J; Hazenberg MD; Ruggeri A;
Lancet Haematol; 2024 Jun; 11(6):e448-e458. PubMed ID: 38796194
[TBL] [Abstract][Full Text] [Related]
33. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M
Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
Guillaume T; Thépot S; Peterlin P; Ceballos P; Bourgeois AL; Garnier A; Orvain C; Giltat A; François S; Bris YL; Fronteau C; Planche L; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):839.e1-839.e6. PubMed ID: 34224913
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis.
Yang L; Tan Y; Shi J; Zhao Y; Yu J; Hu Y; Lai X; Yang Y; Huang H; Luo Y
Bone Marrow Transplant; 2021 Mar; 56(3):664-672. PubMed ID: 33077902
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation.
Gröger M; Gagelmann N; Wolschke C; von Pein UM; Klyuchnikov E; Christopeit M; Zander A; Ayuk F; Kröger N
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1399-1405. PubMed ID: 29684563
[TBL] [Abstract][Full Text] [Related]
39. Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center Experience.
Kerbage F; Sakr R; Lapierre V; Alexandrova K; Coman T; Leroux S; Lucas N; Pilorge S; Solary E; Bourhis JH; Castilla-Llorente C
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):209-211. PubMed ID: 32019730
[TBL] [Abstract][Full Text] [Related]
40. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
